Cohance Lifesciences Receives USFDA Warning Letter for Nacharam Facility
Cohance Lifesciences received a USFDA Warning Letter for its Nacharam, Hyderabad facility. The company stated that US revenues from this facility contributed less than 2% of consolidated revenues in FY2025, with EBITDA contribution below 1%. Cohance is committed to resolving the issues with the USFDA.
The company stated that the affected facility's contribution to consolidated revenues and EBITDA is minimal (less than 2% and 1% respectively), suggesting a limited financial impact.
The company has received a Warning Letter from the USFDA, which is a negative regulatory development.
Cohance Lifesciences Limited has received a Warning Letter from the U.S. Food and Drug Administration (USFDA) concerning its Finished Dosage Formulations (FDF) manufacturing facility located at Nacharam, Hyderabad. This follows an inspection conducted by the USFDA from August 4, 2025, to August 12, 2025, during which the facility was classified as Official Action Indicated (OAI).
The company stated its commitment to addressing the concerns raised by the USFDA and working towards resolving these issues at the earliest. Cohance Lifesciences also highlighted that in FY2025, US revenues from this specific facility contributed less than 2% of consolidated revenues, with a related EBITDA contribution below 1%, indicating no material impact on overall financials.
The company reiterated its commitment to maintaining the highest standards of quality and regulatory compliance across all its operations, ensuring the supply of high-quality pharmaceutical products for global markets. This disclosure is in continuation of previous communications dated August 13, 2025, September 18, 2025, and October 26, 2025.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.